Literature DB >> 29351095

The Effect of Ketorolac on Thoracolumbar Posterolateral Fusion: A Systematic Review and Meta-Analysis.

Jesse Li1, Remi M Ajiboye1, Michael H Orden2, Akshay Sharma3, Austin Drysch1, Sina Pourtaheri4.   

Abstract

STUDY
DESIGN: Systematic review and meta-analysis.
OBJECTIVE: The purpose of this study was to evaluate the effect of postoperative ketorolac administration (ie, dosage and duration of use) on pseudarthrosis following thoracolumbar posterolateral spinal fusions. SUMMARY OF BACKGROUND DATA: Ketorolac is a nonsteroidal anti-inflammatory drug often administered for pain control after spine surgery. The main concern with ketorolac is the risk of pseudarthrosis following fusion.
MATERIALS AND METHODS: A systematic search of multiple medical reference databases was conducted for studies detailing postoperative ketorolac use in lumbar fusion and scoliosis surgery in adult and pediatric patients, respectively. Meta-analysis was performed using the random-effects model for heterogeneity as this study analyzes heterogenous patient populations undergoing variable approaches to fusion and variable numbers of levels with variable means of detection of pseudarthrosis. Outcome measure was pseudarthrosis.
RESULTS: Overall, 6 studies totaling 1558 patients were reviewed. Pseudarthrosis was observed in 119 (7.6%) patients. Pseudarthrosis were observed in adults with ketorolac administered for >2 days [odds ratio (OR), 3.44, 95% confidence interval (95% CI), 1.87-6.36; P<0.001], adults with doses of ≥120 mg/d (OR, 2.93, 95% CI, 1.06-8.12; P=0.039), and adults with ketorolac administered for >2 days and at doses ≥120 mg/d (OR, 4.75, 95% CI, 2.34-9.62; P<0.001). Ketorolac use in smokers was associated with pseudarthrosis (OR, 8.71, 95% CI, 2.23-34.0; P=0.002).
CONCLUSION: Ketorolac, when administered for >2 days and/or at a dose of ≥120 mg/d, is associated with pseudarthrosis in adults after posterolateral lumbar fusion. Ketorolac use in smokers is also associated with pseudarthrosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29351095     DOI: 10.1097/BSD.0000000000000613

Source DB:  PubMed          Journal:  Clin Spine Surg        ISSN: 2380-0186            Impact factor:   1.876


  7 in total

1.  Outpatient Minimally Invasive Lumbar Fusion Using Multimodal Analgesic Management in the Ambulatory Surgery Setting.

Authors:  James M Parrish; Nathaniel W Jenkins; Thomas S Brundage; Nadia M Hrynewycz; Jeffrey Podnar; Asokumar Buvanendran; Kern Singh
Journal:  Int J Spine Surg       Date:  2020-12-29

2.  The Impact of Intraoperative Local Ketorolac on Opioid Use in the Management of Postoperative Pain in Thoracolumbar Spinal Fusions: A Retrospective Cohort Study.

Authors:  Evan Lytle; Chad Claus; Elise Yoon; Doris Tong; Teck Soo
Journal:  Int J Spine Surg       Date:  2020-06-30

Review 3.  The effect of non-steroidal anti-inflammatory medications on spinal fracture healing: a systematic review.

Authors:  Joshua David Piche; Stefano Muscatelli; Arya Ahmady; Rakesh Patel; Ilyas Aleem
Journal:  J Spine Surg       Date:  2021-12

4.  The Benefits of Opioid Free Anesthesia and the Precautions Necessary When Employing It.

Authors:  Christian Bohringer; Carlos Astorga; Hong Liu
Journal:  Transl Perioper Pain Med       Date:  2020

Review 5.  Anesthesia and postoperative pain control-multimodal anesthesia protocol.

Authors:  Alisha Bhatia; Asokumar Buvanendran
Journal:  J Spine Surg       Date:  2019-09

Review 6.  Failures in Thoracic Spinal Fusions and Their Management.

Authors:  Marc Prablek; John McGinnis; Sebastian J Winocour; Edward M Reece; Udaya K Kakarla; Michael Raber; Alexander E Ropper; David S Xu
Journal:  Semin Plast Surg       Date:  2021-05-10       Impact factor: 2.314

Review 7.  Failure in Lumbar Spinal Fusion and Current Management Modalities.

Authors:  Alex Cruz; Alexander E Ropper; David S Xu; Michael Bohl; Edward M Reece; Sebastian J Winocour; Edward Buchanan; Geoffrey Kaung
Journal:  Semin Plast Surg       Date:  2021-05-10       Impact factor: 2.314

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.